- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04847362
The Effect of Tele-Health Education Provided in the Postpartum Period in the Covid 19 Pandemic
22 novembre 2021 mis à jour par: YASEMİN AYDIN KARTAL, Saglik Bilimleri Universitesi
Investigation of the Effect of Tele-Health Education Provided in the Postpartum Period in the Covid 19 Pandemic on the Depression, Attachment and Anxiety Levels of Women: A Randomized Controlled Study
In the planned study, it was aimed to examine the effect of tele-education offered in the postpartum period in the covid 19 pandemic on the levels of depression, attachment and anxiety of women.
Aperçu de l'étude
Statut
Recrutement
Les conditions
Intervention / Traitement
Description détaillée
In the planned study, it was aimed to examine the effect of tele-education offered in the postpartum period in the covid 19 pandemic on the levels of depression, attachment and anxiety of women.
Type d'étude
Interventionnel
Inscription (Anticipé)
74
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Istanbul, Turquie
- Recrutement
- Sağlık Bilimleri Üniversitesi
-
Contact:
- YASEMİN AYDIN KARTAL
- Numéro de téléphone: +90 5432870029
- E-mail: yasemin.aydin@sbu.edu.tr
-
İstanbul, Turquie, 34668
- Recrutement
- Zeynep Kamil Women's and Children's Diseases Training and Research Hospital
-
Contact:
- LEYLA KAYA
- Numéro de téléphone: +90 5456439482
- E-mail: leylakaya02@hotmail.com
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 35 ans (Adulte)
Accepte les volontaires sains
Oui
Sexes éligibles pour l'étude
Femelle
La description
inclusion Criteria
- literate
- Giving birth at term (between 38-42 weeks of gestation)
- Being on the 7th Postpartum Day,
- Participation in the study is voluntary,
- Absence of any psychiatric illness,
- Women who have characteristics such as not using any psychiatric medication.
- Baby with normal birth weight and APGAR score of 8 and above
- Those who have not developed postpartum complications
- Speaks and understands Turkish
Exclusion Criteria:
women who do not meet the sample selection criteria
-
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Experimental
The mothers in this group will be given telehealth training for 4 weeks.
|
education group
|
|
Aucune intervention: Control
Mothers in this group will not be given telehealth education, they will receive care within the scope of routine care.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
postpartum depression
Délai: postpartum 6 weeks
|
The Edinburgh Postnatal Depression Scale (EPDS) was used to detect depressive symptoms during the postpartum period [30].
EPDS is a 10-item questionnaire assessing the interviewee's depressive feelings from the seven days before the interview.
The response of the questions is scored from 0-3, with higher scores indicating higher levels of depressive symptoms.
The total EPDS score of a respondentcan range from 0 to 30.
|
postpartum 6 weeks
|
|
postpartum depression
Délai: postpartum 3 months
|
The Edinburgh Postnatal Depression Scale (EPDS) was used to detect depressive symptoms during the postpartum period [30].
EPDS is a 10-item questionnaire assessing the interviewee's depressive feelings from the seven days before the interview.
The response of the questions is scored from 0-3, with higher scores indicating higher levels of depressive symptoms.
The total EPDS score of a respondentcan range from 0 to 30.
|
postpartum 3 months
|
|
postpartum mother-baby attachment
Délai: postpartum 6 weeks a
|
Postpartum Attachment Scale: Early diagnosis of problems in mother-infant relationship Developed to provide and maternal filling4.
The scale is a six-digit It has a Likert scale.
Scale "always", Postpartum attachment scales in mothers 247 "Very often", "often", "sometimes", "rarely", "no It has been defined as "time".
Items 0-5 It is rated as.
Scale 17 is reverse It consists of 25 graded items.
Scale "attachment disorder" (12 items), "Rejection and irritability" (seven items), "care tension about "(four items), abuse four sub-categories with risk (two substances) It consists of units.
Pathology in mother-infant relationship cut point specified for four subscales 4'18 The cut-off point of four subscales attachment disorder (subscale 1), respectively> 12, rejection and irritability (subscale 2)> 17, anxiety in infant care (subscale 3)> 10, the risk of abuse (subscale 4) is> 3.
|
postpartum 6 weeks a
|
|
postpartum mother-baby attachment
Délai: postpartum 3 months
|
Postpartum Attachment Scale: Early diagnosis of problems in mother-infant relationship Developed to provide and maternal filling4.
The scale is a six-digit It has a Likert scale.
Scale "always", Postpartum attachment scales in mothers 247 "Very often", "often", "sometimes", "rarely", "no It has been defined as "time".
Items 0-5 It is rated as.
Scale 17 is reverse It consists of 25 graded items.
Scale "attachment disorder" (12 items), "Rejection and irritability" (seven items), "care tension about "(four items), abuse four sub-categories with risk (two substances) It consists of units.
Pathology in mother-infant relationship cut point specified for four subscales 4'18 The cut-off point of four subscales attachment disorder (subscale 1), respectively> 12, rejection and irritability (subscale 2)> 17, anxiety in infant care (subscale 3)> 10, the risk of abuse (subscale 4) is> 3.
|
postpartum 3 months
|
|
anxiety state
Délai: postpartum 6 weeks
|
State Anxiety Scale (STAI-I) in 1970 Turkish form developed by Spielberger Oner N et al.
Its validity and reliability study has been carried out by adapting it.
Anxiety level In STAI-I, "(1) not at all, (2) a little, (3) a lot and (4) completely" While it is scored as, the options in STAI-II are (1) almost never, (2) sometimes, (3) a lot of time, and (4) it is almost always.
2 kinds of scales Scores obtained from both scales theoretically it ranges from 20 to 80. High score indicates high anxiety level
|
postpartum 6 weeks
|
|
anxiety state
Délai: postpartum 3 months
|
State Anxiety Scale (STAI-I) in 1970 Turkish form developed by Spielberger Oner N et al.
Its validity and reliability study has been carried out by adapting it.
Anxiety level In STAI-I, "(1) not at all, (2) a little, (3) a lot and (4) completely" While it is scored as, the options in STAI-II are (1) almost never, (2) sometimes, (3) a lot of time, and (4) it is almost always.
2 kinds of scales Scores obtained from both scales theoretically it ranges from 20 to 80. High score indicates high anxiety level
|
postpartum 3 months
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
11 avril 2021
Achèvement primaire (Anticipé)
22 novembre 2021
Achèvement de l'étude (Anticipé)
30 janvier 2022
Dates d'inscription aux études
Première soumission
12 avril 2021
Première soumission répondant aux critères de contrôle qualité
14 avril 2021
Première publication (Réel)
19 avril 2021
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
23 novembre 2021
Dernière mise à jour soumise répondant aux critères de contrôle qualité
22 novembre 2021
Dernière vérification
1 novembre 2021
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Symptômes comportementaux
- Les troubles mentaux
- Infections à coronavirus
- Infections à Coronaviridae
- Infections à Nidovirales
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections des voies respiratoires
- Maladies des voies respiratoires
- Troubles de l'humeur
- Pneumonie virale
- Pneumonie
- Maladies pulmonaires
- Complications de grossesse
- Troubles puerpéraux
- La dépression
- Dépression
- COVID-19 [feminine]
- Troubles anxieux
- Dépression, post-partum
Autres numéros d'identification d'étude
- 11.04.2021-27076
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
INDÉCIS
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .